CoChat

Anxiety, Depression, and Impaired Quality of Life in Primary Aldosteronism: Why We Shouldn’t Ignore It!

Open access
Reincke, Martin · 2018 · The Journal of Clinical Endocrinology & Metabolism
Cited by 40

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Many endocrinopathies are associated with impaired quality of life and psychiatric comorbidities. Personality changes are characteristic features of endocrine diseases and can even be the dominating symptom. In such circumstances, a patient will be treated for an apparent primary psychiatric condition, whereas the underlying endocrine diagnosis is delayed for month or even years. It is textbook knowledge that mania and psychosis may be found in patients with severe hyperthyroidism, whereas patients with Cushing syndrome frequently have depressive symptoms and cognitive disturbances. In pituitary diseases, the spectrum depends on the underlying hyperfunction or hypofunction: acromegalic patients often have maladaptive personality traits and higher rates of affective disorders, and patients with prolactinoma have changes in sleep pattern and cognition. Primary aldosteronism affects, depending on hypertension prevalence in the respective target populations, 1% to 2% of the general population (1). It comes with an increased risk of cardiovascular and renal comorbidities compared with hypertensive patients of similar age, sex, and blood pressure. Contrary to other endocrinopathies, psychiatric comorbidities in patients with primary aldosteronism have only recently become a focus of attention. Several early case reports identified depression and anxiety disorders as symptoms associated with primary aldosteronism (2–5). It was not until 2006 that Sonino et al. (6) investigated 10 consecutive patients with primary aldosteronism using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders and the Diagnostic Criteria for Psychosomatic Research interview. As it turned out, seven patients qualified for the diagnosis of a generalized anxiety disorder, and one patient had an obsessive-compulsive disorder (Table 1 and Table 2) (6–11). The patients also reported demoralization (n = 5), persistent somatization (n = 2), and irritable mood (n = 1). In a controlled study, the same authors confirmed this finding in an independent cohort of 23 patients with primary aldosteronism in comparison with matched essential hypertensive patients and normotensive controls (7). Again, there was a striking prevalence of anxiety and, to a lesser degree, depression in the patients. Prevalence of Depression and Anxiety in Patients With Primary Aldosteronism Abbreviations: DCPR, Diagnostic Criteria for Psychosomatic Research; EH, essential hypertension; GAD-7, seven-item General Anxiety Disorder scale; MRA, mineralocorticoid receptor antagonist; NA, not available; PA, primary aldosteronism; PHQD, Brief Patient Health Questionnaire; PSI, Psychosocial Index; SCID, Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV. Prevalence of Depression and Anxiety in Patients With Primary Aldosteronism Abbreviations: DCPR, Diagnostic Criteria for Psychosomatic Research; EH, essential hypertension; GAD-7, seven-item General Anxiety Disorder scale; MRA, mineralocorticoid receptor antagonist; NA, not available; PA, primary aldosteronism; PHQD, Brief Patient Health Questionnaire; PSI, Psychosocial Index; SCID, Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV. Prevalence of Impaired Quality of Life in Patients With Primary Aldosteronism Abbreviations: MRA, mineralocorticoid receptor antagonist; PA, primary aldosteronism; QoL, quality of life; SF-36, Medical Outcomes Study Short Form 36 General Health Survey. Prevalence of Impaired Quality of Life in Patients With Primary Aldosteronism Abbreviations: MRA, mineralocorticoid receptor antagonist; PA, primary aldosteronism; QoL, quality of life; SF-36, Medical Outcomes Study Short Form 36 General Health Survey. In a large cross-sectional study, we studied 132 patients with primary aldosteronism in different phases of the disease: at diagnosis before initiation of specific treatment, 4 years after adrenalectomy, or 5 years after initiation of mineralocorticoid antagonist treatment (8). We assessed anxiety and depression by the following validated questionnaires: seven-item General Anxiety Disorder scale and Brief Patient Health Questionnaire. Compared with the normal German population, patients with primary aldosteronism had higher prevalence rates of depression and anxiety, with females being more severely affected than males. The first study to investigate the longitudinal impact of adrenalectomy and mineralocorticoid antagonist treatment on quality of life was the Stowasser group from Australia. In their pilot study, quality of life was evaluated prospectively using the Medical Outcomes Study Short Form 36 General Health Survey questionnaire before and 3 and 6 months after unilateral adrenalectomy in 22 patients with primary aldosteronism (9). Preoperatively, the patients had impaired quality of life in each quality-of-life domain compared with the Australian general population. Substanti

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2017-02141

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 40

Metadata

Authors
Reincke, M.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2017-11-01
Volume
103
Issue
1
Pages
1-4
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2765264971
Cited by
40
References
2
FWCI
4.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.